1 results
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2023-505455-44-00 check the CTIS register for the current data. Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity…